Passaro, A <br/><br/>
Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.  [electronic resource] 

 -  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico  Apr 2020 
 - 603-611 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1699-3055 
<br/><br/><label>Standard No.: </label>10.1007/s12094-019-02166-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Biomarkers<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Female<br/>Granulocytes--physiology<br/>Humans<br/>Immune Checkpoint Inhibitors--therapeutic use<br/>Immunophenotyping<br/>Immunotherapy<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Myeloid-Derived Suppressor Cells--physiology<br/>Nivolumab--therapeutic use<br/>Prospective Studies